A year after raising $66m in a series B, the Zug, Switzerland-headquartered start-up biotech, Pharvaris B.V. has just raised a hefty $80m in a series C round, with its lead product expected to enter Phase II clinical trials in 2021.
Pharvaris Oral HAE Candidate Heading Into Phase II In 2021
$80m Series C Completed
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
More from Cardiovascular
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.